Stock Traders Purchase Large Volume of Teladoc Health Call Options (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) saw some unusual options trading on Thursday. Investors purchased 15,650 call options on the company. This is an increase of 30% compared to the typical volume of 12,026 call options.

Teladoc Health Stock Down 28.4%

Teladoc Health stock opened at $6.58 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The stock has a market capitalization of $1.19 billion, a PE ratio of -6.64 and a beta of 2.10. The business has a 50 day simple moving average of $8.21 and a 200-day simple moving average of $6.54. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 12.02% and a negative net margin of 7.13%.The firm had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. During the same quarter last year, the firm posted ($0.19) EPS. The business’s revenue was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, analysts anticipate that Teladoc Health will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TDOC has been the topic of several analyst reports. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Bank of America lifted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Canaccord Genuity Group decreased their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Citigroup increased their target price on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.50.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles Divita III sold 19,132 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $145,977.16. Following the sale, the chief executive officer owned 389,894 shares in the company, valued at approximately $2,974,891.22. This represents a 4.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Fernando M. Rodrigues sold 5,677 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $43,315.51. Following the sale, the insider directly owned 9,572 shares in the company, valued at $73,034.36. The trade was a 37.23% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 39,195 shares of company stock valued at $299,058. Insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TDOC. IFP Advisors Inc increased its stake in shares of Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after purchasing an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after buying an additional 2,810 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Teladoc Health by 694.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock valued at $31,000 after buying an additional 4,945 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Teladoc Health in the 4th quarter valued at about $45,000. Finally, Versant Capital Management Inc boosted its holdings in Teladoc Health by 33.3% in the 2nd quarter. Versant Capital Management Inc now owns 8,207 shares of the health services provider’s stock worth $70,000 after buying an additional 2,052 shares during the last quarter. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter loss of $0.21 per share, better than the expected $0.24 loss. Integrated Care and international operations showed relative strength, helping offset weakness elsewhere. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Canaccord Genuity maintained a “buy” rating while lowering its price target from $11 to $10, implying substantial potential upside from recent trading levels. Unusual options activity also indicated increased call buying, although it is not a fundamental catalyst. Benzinga analyst and options activity report
• Neutral Sentiment: Management’s cost controls appear to be narrowing losses and supporting cash generation: second-quarter operating cash flow was approximately $64.7 million, while cash and equivalents totaled about $774.3 million. However, the company remains unprofitable. Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path?
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, below analysts’ approximately $615.4 million forecast. The revenue miss was more important to investors than the adjusted earnings beat because it signals continued difficulty producing top-line growth. Teladoc Stock Plummets on Revenue Miss, Lowered Outlook
• Negative Sentiment: The main pressure came from BetterHelp, where changing demand patterns reduced mental-health services revenue. Stronger Integrated Care performance did not fully offset the weakness. Teladoc tumbles on revenue forecast cut as BetterHelp demand shifts hurt
• Negative Sentiment: Teladoc issued a soft third-quarter outlook, forecasting revenue of $569 million to $609 million versus consensus of roughly $629 million, and an EPS loss of $0.20 to $0.30 versus an expected $0.17 loss. Full-year revenue guidance was also reduced to about $2.4 billion, below the $2.5 billion consensus. Why Teladoc Health Stock Is Dropping Following Soft Q3 Outlook

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.